The Supreme Court’s recent decision to hear an appeal regarding access to the abortion pill mifepristone has reignited the ongoing debate on abortion in the United States.
This decision, expected to be made in June, carries significant implications for abortion access across the country.
The Role of Mifepristone in Abortion
Mifepristone, approved in 2000, is a key component of a two-drug treatment regimen widely used in the United States to terminate pregnancies within the first 10 weeks of gestation.
According to the Guttmacher Institute, approximately half of all abortions in the country are performed using mifepristone. The drug’s approval and subsequent changes in regulations have sparked controversy and legal challenges.
Read: Minor’s Abortion Blocked In Florida Under Consent Law
The Journey to the Supreme Court
The Supreme Court’s involvement in the mifepristone case came after the U.S. Court of Appeals for the 5th Circuit ruled in August that while mifepristone could remain on the market in states where abortion is legal, certain changes made by the Food and Drug Administration (FDA) since 2016 were not allowed.
These changes included increasing the gestational age for mifepristone usage, allowing medication to be mailed to patients, and expanding the range of healthcare providers authorized to prescribe the drug.
The Supreme Court granted a request from the Justice Department and the manufacturer of mifepristone, Danco, to hear the case. However, the court declined to review a request from anti-abortion plaintiffs to reinstate a lower court’s ban on the drug.
This decision signifies the court’s willingness to weigh in on abortion-related matters, despite its conservative majority’s previous stance that such questions should be left to elected officials.
Potential Outcomes and their Implications
Option 1: Upholding the Fifth Circuit Decision
If the Supreme Court upholds the Fifth Circuit’s ruling, it would be a victory for the Alliance Defending Freedom, the far-right group representing the anti-abortion providers in the case. While mifepristone would remain on the market, access to the drug would become more challenging. This decision would have significant implications for abortion access nationwide and could undermine the FDA’s authority in approving drugs. Manufacturers would need to alter the drug’s label, and the FDA would have to rewrite its rules and regulations for distribution and use, causing delays in availability. Additionally, the higher dosage of mifepristone poses greater risks to patients.
Option 2: Reversing the Fifth Circuit Decision
The White House, Danco Laboratories, and abortion-rights advocates are urging the Supreme Court to reverse the Fifth Circuit’s ruling. This outcome would maintain the status quo, with mifepristone remaining on the market without any changes. States that currently restrict the prescribing and mailing of mifepristone would still be allowed to do so. Reversing the Fifth Circuit’s decision would be a blow to anti-abortion groups, as legal experts have questioned the validity of their arguments. Solicitor General Elizabeth Prelogar emphasized the potential damaging consequences for women seeking lawful abortions and the healthcare system if the appeals court’s decision were to take effect.
Read: Florida Abortion Measure Tops 753K Signatures
Option 3: A Different Outcome
While legal experts hesitate to predict the Supreme Court’s decision, there is a possibility that the court could uphold some changes made since 2016 while invalidating others. Such an outcome would introduce further uncertainty and potential restrictions to abortion access. Abortion providers and advocates suggest that pregnancies could still be terminated using misoprostol, the second drug in the regimen. However, using misoprostol alone is less effective and causes more discomfort. If mifepristone access is limited, opponents of abortion could target the use of misoprostol as well.
The Potential Impact on Reproductive Rights
The Supreme Court’s decision in this case has far-reaching implications for reproductive rights in the United States. Upholding the Fifth Circuit’s decision or introducing further restrictions could disrupt abortion access across the country, even in states where abortion remains legal and protected.
It would set a precedent for broad lawsuits challenging FDA approvals and undermine the agency’s authority in regulating drugs. The ability of healthcare providers, other than physicians, to prescribe mifepristone could also be jeopardized. The outcome of this case will determine whether access to safe and legal abortions remains protected or faces significant obstacles.
Potential Impact on the Pharmaceutical Industry
The Supreme Court’s decision in this case also has implications for the biopharmaceutical industry and the FDA’s approval process. The anti-abortion group behind the challenge argues that the FDA did not adequately consider safety concerns when approving mifepristone or when making subsequent changes.
A ruling in favor of these arguments could raise questions about the FDA’s reliance on scientific studies and its ability to determine conditions of use. This uncertainty could have a destabilizing effect on the pharmaceutical and biotechnology industries, potentially impacting their research, development, and approval processes.
Android Users, Click To Download The Free Press App And Never Miss A Story. Follow Us On Facebook and Twitter. Sign up for our free newsletter.
We can’t do this without your help. Visit our GiveSendGo page and donate any dollar amount; every penny helps.